Journal: Open Forum Infectious Diseases

Article Title: A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV

doi: 10.1093/ofid/ofac579

Figure Lengend Snippet: Study Characteristics

Article Snippet: Huang, 2022, China , Prospective cross-sectional study , 120 PWH, 53 controls , 630.5 cells/mm 3 (IQR 499.5–848.8) , 58.1% ≤60 copies/mL, 25.6% 61–200 copies/mL, 16.3% >200 copies/mL , Sinovac CoronaVac (55% PWH, 30.2% controls); Sinopharm BBIBP-CorV (45% PWH, 69.8 controls) , 0–84+ d , 96.2% PWH, 100% controls , A/CO ratio ≥1.0 , Median: 6.8 PWH, 10.1 controls , IQR: 3.3–12.1 PWH, 6.5–19.4 controls , A/CO ratio , Wantai SARS-CoV-2 IgG total and anti-S-IgG; A/CO ratio ≥1.0 , NR.

Techniques: Cell Counting, Variant Assay, Concentration Assay, Enzyme-linked Immunosorbent Assay, Infection, Standard Deviation, Microarray, Inhibition, Recombinant, Clinical Proteomics

Journal: Open Forum Infectious Diseases

Article Title: A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV

doi: 10.1093/ofid/ofac579

Figure Lengend Snippet: Study Summary

Article Snippet: Huang, 2022, China , Prospective cross-sectional study , 120 PWH, 53 controls , 630.5 cells/mm 3 (IQR 499.5–848.8) , 58.1% ≤60 copies/mL, 25.6% 61–200 copies/mL, 16.3% >200 copies/mL , Sinovac CoronaVac (55% PWH, 30.2% controls); Sinopharm BBIBP-CorV (45% PWH, 69.8 controls) , 0–84+ d , 96.2% PWH, 100% controls , A/CO ratio ≥1.0 , Median: 6.8 PWH, 10.1 controls , IQR: 3.3–12.1 PWH, 6.5–19.4 controls , A/CO ratio , Wantai SARS-CoV-2 IgG total and anti-S-IgG; A/CO ratio ≥1.0 , NR.

Techniques: Vaccines, Immunopeptidomics, Generated, Cell Counting, Variant Assay, Produced, Infection

Journal: Open Forum Infectious Diseases

Article Title: A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV

doi: 10.1093/ofid/ofac579

Figure Lengend Snippet: COVID-19 vaccine seroconversion rates in PWH and HIV-negative individuals by vaccine type. Solid diamonds: mRNA (BNT162b2, mRNA-1273). Solid upward triangles: Viral vector (ChAdOx1, Ad26.COV2.S). Solid downward triangles: Inactivated virus (BBIBP-CorV, CoronaVac). Solid squares: Multiplec. Hollow rectangles: HIV-negative. Solid rectangles: PWH. aThe Levy and Rahav studies may have overlap in the patients observed. Ogbe and Frater also had overlapping patients, but Ogbe did not report seroconversion rates and is therefore not included in this figure. bThe Nault and Ruddy (1) studies reported seroconversion rates only after the first dose of a 2-dose mRNA vaccine regimen. cIncludes studies using multiple vaccine types (eg, mRNA, viral vector): Brumme (BNT162b2, mRNA-1273, ChAdOx1), Haidar (BNT162b2, mRNA-1273, Ad26.COV2.S), Hassold (BNT162b2, mRNA-1273, ChAdOx1), Noe (BNT162b2, mRNA-1273, ChAdOx1, Ad26.COV2.S). Abbreviations: COVID-19, coronavirus disease 2019; PWH, people with HIV.

Article Snippet: Huang, 2022, China , Prospective cross-sectional study , 120 PWH, 53 controls , 630.5 cells/mm 3 (IQR 499.5–848.8) , 58.1% ≤60 copies/mL, 25.6% 61–200 copies/mL, 16.3% >200 copies/mL , Sinovac CoronaVac (55% PWH, 30.2% controls); Sinopharm BBIBP-CorV (45% PWH, 69.8 controls) , 0–84+ d , 96.2% PWH, 100% controls , A/CO ratio ≥1.0 , Median: 6.8 PWH, 10.1 controls , IQR: 3.3–12.1 PWH, 6.5–19.4 controls , A/CO ratio , Wantai SARS-CoV-2 IgG total and anti-S-IgG; A/CO ratio ≥1.0 , NR.

Techniques: Plasmid Preparation, Virus